Symbols / ABVX Stock $101.53 -3.24% ABIVAX Société Anonyme
ABVX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Ratings
Current target
$101.53
Low
$90.00
High
$187.00
Mean
$149.09
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-06-02 | main | Truist Securities | Buy → Buy | $135 |
| 2026-06-02 | down | Jefferies | Buy → Hold | $90 |
| 2026-06-02 | main | Morgan Stanley | Overweight → Overweight | $132 |
| 2026-06-02 | up | Wedbush | Underperform → Neutral | $90 |
| 2026-06-02 | main | Citizens | Market Outperform → Market Outperform | $187 |
| 2026-06-02 | reit | BTIG | Buy → Buy | $150 |
| 2026-05-26 | reit | Citizens | Market Outperform → Market Outperform | $131 |
| 2026-03-24 | main | Barclays | Overweight → Overweight | $148 |
| 2026-03-16 | init | Jefferies | — → Buy | $160 |
| 2026-02-25 | reit | BTIG | Buy → Buy | $150 |
| 2026-02-24 | init | Wedbush | — → Underperform | $110 |
| 2026-01-09 | main | Morgan Stanley | Overweight → Overweight | $145 |
| 2026-01-08 | main | BTIG | Buy → Buy | $150 |
| 2025-12-16 | main | Citizens | Market Outperform → Market Outperform | $131 |
| 2025-11-24 | init | Truist Securities | — → Buy | $140 |
| 2025-11-06 | init | Wolfe Research | — → Outperform | $176 |
| 2025-10-13 | init | Barclays | — → Overweight | $142 |
| 2025-10-10 | main | Guggenheim | Buy → Buy | $150 |
| 2025-10-07 | main | BTIG | Buy → Buy | $120 |
| 2025-09-25 | main | JMP Securities | Market Outperform → Market Outperform | $114 |
- Abivax Drops 32% On Cancer Signal: Jefferies Warns Of ‘Real’ Overhang But Retail Calls Selloff An ‘Overreaction’ - Yahoo Finance ue, 02 Jun 2026 11
- Abivax slides as traders digest recent trial updates and potential selling from a fresh ADS deal - Quiver Quantitative Mon, 01 Jun 2026 21
- ABVX Stock Clocks Worst Day Ever On Malignancy Signal For Drug: ‘Pharma Bro’ Says ‘GLPs Are Doing Fine’ After Similar Fears - Stocktwits Fri, 05 Jun 2026 00
- ABVX Stock Rebounds As Obefazimod Data Resets Expectations - StocksToTrade hu, 04 Jun 2026 14
- Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX) - PR Newswire Wed, 03 Jun 2026 01
- ABVX News | ABIVAX SA-ADR (NASDAQ:ABVX) - ChartMill Mon, 01 Jun 2026 07
- What's Going On With Abivax Stock On Thursday? - Benzinga hu, 04 Jun 2026 14
- ABVX Stock Whipsaws As Obefazimod Data Ignite Volatile Trading - timothysykes.com hu, 04 Jun 2026 21
- ABVX Archives - 24/7 Wall St. ue, 02 Jun 2026 12
- ABVX Tanks 30% After-Hours Despite 51% Remission In Ulcerative Colitis Trial — Rare Cancer Concerns Hit Sentiment - Stocktwits Sat, 06 Jun 2026 08
- Abivax SA Sponsored ADR (ABVX) Loses 41.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance Wed, 03 Jun 2026 13
- ABVX Stock Whipsaws As Obefazimod Trial Data Ignite Volatility - StocksToTrade hu, 04 Jun 2026 20
- ABVX Stock Rebounds As Obefazimod Data Reshape Bull Thesis - timothysykes.com hu, 04 Jun 2026 18
- Abivax (ABVX) Skyrockets 24% After Steep Fall - Yahoo Finance hu, 04 Jun 2026 02
- ABVX Stock Plunges As Safety Debate Overshadows Strong Trial Win - StocksToTrade Wed, 03 Jun 2026 16
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
—
|
—
|
—
|
50.76
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
—
|
50.53
|
| Gross Profit |
|
—
|
—
|
—
|
-50.76
|
| Operating Expense |
|
246.06
+42.24%
|
172.98
+35.80%
|
127.38
+148.76%
|
51.20
|
| Research And Development |
|
177.76
+21.31%
|
146.53
+42.02%
|
103.18
+113.64%
|
48.30
|
| Selling General And Administration |
|
72.86
+87.31%
|
38.90
+34.97%
|
28.82
+284.65%
|
7.49
|
| Selling And Marketing Expense |
|
0.22
-75.97%
|
0.93
+31.45%
|
0.71
|
0.00
|
| General And Administrative Expense |
|
72.64
+91.32%
|
37.97
+35.05%
|
28.11
+275.19%
|
7.49
|
| Salaries And Wages |
|
56.16
+158.14%
|
21.76
+46.86%
|
14.81
+955.95%
|
1.40
|
| Other Gand A |
|
16.48
+1.64%
|
16.21
+21.91%
|
13.30
+118.36%
|
6.09
|
| Other Operating Expenses |
|
-4.57
+63.29%
|
-12.45
-169.38%
|
-4.62
-0.83%
|
-4.58
|
| Total Expenses |
|
246.06
+42.24%
|
172.98
+35.80%
|
127.38
+148.76%
|
51.20
|
| Operating Income |
|
-246.06
-42.24%
|
-172.98
-35.80%
|
-127.38
-148.76%
|
-51.20
|
| Total Operating Income As Reported |
|
-246.06
-42.24%
|
-172.98
-35.81%
|
-127.38
-96.46%
|
-64.84
|
| EBITDA |
|
-300.70
-84.81%
|
-162.71
-22.15%
|
-133.21
-149.85%
|
-53.31
|
| Normalized EBITDA |
|
-268.99
-62.64%
|
-165.38
-35.17%
|
-122.36
-149.45%
|
-49.05
|
| Reconciled Depreciation |
|
1.07
-2.55%
|
1.10
+55.59%
|
0.71
+45.77%
|
0.48
|
| EBIT |
|
-301.77
-84.22%
|
-163.81
-22.33%
|
-133.91
-148.91%
|
-53.80
|
| Total Unusual Items |
|
-31.71
-1285.90%
|
2.67
+124.64%
|
-10.85
-154.38%
|
-4.27
|
| Total Unusual Items Excluding Goodwill |
|
-31.71
-1285.90%
|
2.67
+124.64%
|
-10.85
-154.38%
|
-4.27
|
| Special Income Charges |
|
-3.84
|
0.00
+100.00%
|
-3.24
+76.24%
|
-13.63
|
| Other Special Charges |
|
3.84
|
—
|
3.24
-76.65%
|
13.87
|
| Impairment Of Capital Assets |
|
—
|
0.00
|
0.00
-100.00%
|
13.63
|
| Restructuring And Mergern Acquisition |
|
—
|
1.37
+142.75%
|
-3.20
-121.16%
|
-1.45
|
| Net Income |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Pretax Income |
|
-330.25
-87.39%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Net Non Operating Interest Income Expense |
|
-52.49
-784.94%
|
-5.93
+37.63%
|
-9.51
-80.42%
|
-5.27
|
| Interest Expense Non Operating |
|
28.48
+129.12%
|
12.43
-10.09%
|
13.83
+99.22%
|
6.94
|
| Net Interest Income |
|
-52.49
-784.94%
|
-5.93
+37.63%
|
-9.51
-80.42%
|
-5.27
|
| Interest Expense |
|
28.48
+129.12%
|
12.43
-10.09%
|
13.83
+99.22%
|
6.94
|
| Interest Income Non Operating |
|
5.75
-35.76%
|
8.96
+222.97%
|
2.77
|
0.00
|
| Interest Income |
|
5.75
-35.76%
|
8.96
+222.97%
|
2.77
|
0.00
|
| Other Income Expense |
|
-31.71
-1285.90%
|
2.67
+124.64%
|
-10.85
-154.38%
|
-4.27
|
| Other Non Operating Income Expenses |
|
—
|
-1.37
-142.75%
|
3.20
+121.16%
|
1.45
|
| Gain On Sale Of Security |
|
-27.87
-1142.37%
|
2.67
+135.12%
|
-7.61
-181.28%
|
9.37
|
| Tax Provision |
|
5.85
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
-7.93
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Net Income From Continuing Operation Net Minority Interest |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Net Income From Continuing And Discontinued Operation |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Net Income Continuous Operations |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Normalized Income |
|
-312.32
-74.56%
|
-178.92
-30.70%
|
-136.89
-142.39%
|
-56.47
|
| Net Income Common Stockholders |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
0.00
|
0.00
|
| Diluted EPS |
|
-4.83
-73.65%
|
-2.78
+18.91%
|
-3.43
-7.86%
|
-3.18
|
| Basic EPS |
|
-4.83
-73.65%
|
-2.78
+18.91%
|
-3.43
-7.86%
|
-3.18
|
| Basic Average Shares |
|
69.53
+9.75%
|
63.35
+47.09%
|
43.07
+125.57%
|
19.09
|
| Diluted Average Shares |
|
69.53
+9.75%
|
63.35
+47.09%
|
43.07
+125.57%
|
19.09
|
| Diluted NI Availto Com Stockholders |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
—
|
—
|
0.07
|
| Depreciation And Amortization In Income Statement |
|
—
|
—
|
—
|
0.07
|
| Depreciation Income Statement |
|
—
|
—
|
—
|
0.07
|
| Other Taxes |
|
—
|
—
|
—
|
0.04
|
| Rent And Landing Fees |
|
—
|
—
|
—
|
1.05
|
| Rent Expense Supplemental |
|
—
|
—
|
—
|
1.05
|
| Total Other Finance Cost |
|
29.76
+1111.60%
|
2.46
+259.17%
|
-1.54
+7.55%
|
-1.67
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Assets |
|
327.06
+332.94%
|
75.54
|
—
|
| Current Assets |
|
285.97
+690.39%
|
36.18
|
—
|
| Cash Cash Equivalents And Short Term Investments |
|
260.99
+868.43%
|
26.95
|
—
|
| Cash And Cash Equivalents |
|
251.94
+834.85%
|
26.95
|
—
|
| Cash Equivalents |
|
18.11
-32.81%
|
26.94
|
—
|
| Cash Financial |
|
233.84
+3897183.33%
|
0.01
|
—
|
| Other Short Term Investments |
|
9.05
|
0.00
|
—
|
| Receivables |
|
19.10
+129.67%
|
8.32
|
—
|
| Accounts Receivable |
|
—
|
—
|
1.47
|
| Other Receivables |
|
0.06
-76.38%
|
0.25
+6250.00%
|
0.00
|
| Taxes Receivable |
|
19.04
+136.16%
|
8.06
|
—
|
| Inventory |
|
—
|
—
|
4.00
|
| Work In Process |
|
—
|
—
|
4.00
|
| Prepaid Assets |
|
5.88
+542.84%
|
0.92
|
—
|
| Current Deferred Assets |
|
5.75
+527.98%
|
0.92
+26.91%
|
0.72
|
| Other Current Assets |
|
-0.00
|
—
|
-0.00
|
| Total Non Current Assets |
|
41.09
+4.39%
|
39.36
|
—
|
| Net PPE |
|
0.88
-44.91%
|
1.59
|
—
|
| Gross PPE |
|
2.37
-1.42%
|
2.40
|
—
|
| Accumulated Depreciation |
|
-1.49
-84.28%
|
-0.81
|
—
|
| Properties |
|
0.00
|
0.00
|
—
|
| Buildings And Improvements |
|
1.35
-16.81%
|
1.62
|
—
|
| Machinery Furniture Equipment |
|
0.51
+46.53%
|
0.35
|
—
|
| Construction In Progress |
|
—
|
0.07
+570.00%
|
0.01
|
| Other Properties |
|
0.51
+17.66%
|
0.44
|
—
|
| Goodwill And Other Intangible Assets |
|
25.02
-0.01%
|
25.03
|
—
|
| Goodwill |
|
18.42
+0.00%
|
18.42
|
—
|
| Other Intangible Assets |
|
6.60
-0.05%
|
6.61
|
—
|
| Investments And Advances |
|
0.12
|
0.00
|
—
|
| Non Current Deferred Assets |
|
2.32
+123.72%
|
1.04
|
0.00
|
| Non Current Prepaid Assets |
|
15.07
+28.67%
|
11.71
|
—
|
| Other Non Current Assets |
|
2.32
+123.94%
|
1.04
|
—
|
| Total Liabilities Net Minority Interest |
|
131.05
+91.72%
|
68.36
|
—
|
| Current Liabilities |
|
88.11
+71.22%
|
51.46
|
—
|
| Payables And Accrued Expenses |
|
53.29
+199.83%
|
17.77
|
—
|
| Payables |
|
53.29
+199.83%
|
17.77
|
—
|
| Accounts Payable |
|
47.22
+205.14%
|
15.47
|
—
|
| Other Payable |
|
3.69
+174.04%
|
1.35
+14.24%
|
1.18
|
| Current Accrued Expenses |
|
—
|
0.66
-56.25%
|
1.50
|
| Employee Benefits |
|
0.63
+3.11%
|
0.61
|
—
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
1.16
+114.68%
|
0.54
|
| Total Tax Payable |
|
6.07
+164.04%
|
2.30
|
—
|
| Current Debt And Capital Lease Obligation |
|
31.26
+4.08%
|
30.03
|
—
|
| Current Debt |
|
30.88
+4.72%
|
29.49
+193.07%
|
10.06
|
| Other Current Borrowings |
|
30.88
+4.72%
|
29.49
+193.07%
|
10.06
|
| Current Capital Lease Obligation |
|
0.38
-30.46%
|
0.55
|
—
|
| Current Deferred Liabilities |
|
0.05
-60.90%
|
0.13
|
—
|
| Current Deferred Revenue |
|
0.05
-60.90%
|
0.13
|
—
|
| Other Current Liabilities |
|
3.51
-0.34%
|
3.52
+216.64%
|
1.11
|
| Total Non Current Liabilities Net Minority Interest |
|
42.94
+154.19%
|
16.89
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
26.78
+193.46%
|
9.13
|
—
|
| Long Term Debt |
|
26.62
+221.24%
|
8.29
-76.05%
|
34.61
|
| Long Term Capital Lease Obligation |
|
0.16
-80.93%
|
0.84
|
—
|
| Long Term Provisions |
|
0.03
-25.00%
|
0.04
|
—
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
0.63
+3.11%
|
0.61
|
—
|
| Non Current Deferred Liabilities |
|
0.00
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
0.00
|
—
|
—
|
| Other Non Current Liabilities |
|
15.49
+136.59%
|
6.55
|
—
|
| Stockholders Equity |
|
196.01
+2626.53%
|
7.19
|
—
|
| Common Stock Equity |
|
196.01
+2626.53%
|
7.19
|
—
|
| Capital Stock |
|
0.63
+182.06%
|
0.22
|
—
|
| Common Stock |
|
0.63
+182.06%
|
0.22
|
—
|
| Share Issued |
|
62.93
+182.18%
|
22.30
|
—
|
| Ordinary Shares Number |
|
62.92
+182.13%
|
22.30
|
—
|
| Treasury Shares Number |
|
0.01
-5.51%
|
0.01
+39.53%
|
0.01
|
| Additional Paid In Capital |
|
478.22
+217.80%
|
150.48
|
—
|
| Retained Earnings |
|
-282.95
-97.16%
|
-143.51
|
—
|
| Gains Losses Not Affecting Retained Earnings |
|
0.11
|
0.00
|
—
|
| Total Equity Gross Minority Interest |
|
196.01
+2626.53%
|
7.19
|
—
|
| Total Capitalization |
|
222.63
+1338.48%
|
15.48
|
—
|
| Working Capital |
|
197.86
+1394.71%
|
-15.28
|
—
|
| Invested Capital |
|
253.51
+463.79%
|
44.97
|
—
|
| Total Debt |
|
58.04
+48.22%
|
39.16
|
—
|
| Net Debt |
|
—
|
10.83
|
—
|
| Capital Lease Obligations |
|
0.54
-61.05%
|
1.38
|
—
|
| Net Tangible Assets |
|
170.99
+1058.61%
|
-17.84
|
—
|
| Tangible Book Value |
|
170.99
+1058.61%
|
-17.84
|
—
|
| Available For Sale Securities |
|
0.12
+61.04%
|
0.08
-65.00%
|
0.22
|
| Current Provisions |
|
—
|
—
|
0.16
|
| Derivative Product Liabilities |
|
0.00
-100.00%
|
0.57
|
—
|
| Foreign Currency Translation Adjustments |
|
0.11
|
0.00
|
—
|
| Interest Payable |
|
—
|
0.66
+0.46%
|
0.65
|
| Investmentin Financial Assets |
|
0.12
|
0.00
|
—
|
| Non Current Note Receivables |
|
—
|
1.24
-54.85%
|
2.74
|
| Notes Receivable |
|
0.06
-76.38%
|
0.25
|
—
|
| Other Equity Interest |
|
—
|
6.82
-0.26%
|
6.84
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-161.13
-4.58%
|
-154.07
-58.62%
|
-97.13
-80.08%
|
-53.94
|
| Cash Flow From Continuing Operating Activities |
|
-161.13
-4.58%
|
-154.07
-58.63%
|
-97.13
-80.09%
|
-53.93
|
| Net Income From Continuing Operations |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Depreciation Amortization Depletion |
|
1.07
-2.55%
|
1.10
+55.59%
|
0.71
+45.77%
|
0.48
|
| Depreciation |
|
—
|
—
|
0.71
|
—
|
| Amortization Cash Flow |
|
—
|
—
|
0.00
-100.00%
|
0.31
|
| Depreciation And Amortization |
|
1.07
-2.55%
|
1.10
+55.59%
|
0.71
+45.77%
|
0.48
|
| Amortization Of Intangibles |
|
—
|
—
|
0.00
-100.00%
|
0.31
|
| Other Non Cash Items |
|
22.03
+1174.26%
|
-2.05
-109.52%
|
21.54
+224.66%
|
6.63
|
| Pension And Employee Benefit Expense |
|
-0.07
-187.84%
|
0.07
-32.11%
|
0.11
-23.78%
|
0.14
|
| Stock Based Compensation |
|
35.40
+75.02%
|
20.22
+147.27%
|
8.18
+802.66%
|
-1.16
|
| Provisionand Write Offof Assets |
|
44.71
|
0.00
|
0.00
|
—
|
| Asset Impairment Charge |
|
—
|
0.00
|
0.00
-100.00%
|
13.63
|
| Deferred Tax |
|
5.85
|
0.00
|
0.00
|
—
|
| Deferred Income Tax |
|
5.85
|
0.00
|
0.00
|
—
|
| Operating Gains Losses |
|
62.27
+4124.22%
|
1.47
+236.10%
|
-1.08
+89.96%
|
-10.78
|
| Gain Loss On Investment Securities |
|
62.33
+4352.14%
|
1.40
+217.45%
|
-1.19
+89.09%
|
-10.93
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
—
|
5.57
|
0.00
|
| Change In Working Capital |
|
3.65
+156.64%
|
1.42
-93.31%
|
21.27
+1162.24%
|
-2.00
|
| Change In Receivables |
|
7.04
+53.39%
|
4.59
+132.26%
|
-14.23
-4661.22%
|
0.31
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
—
|
| Change In Payables And Accrued Expense |
|
-4.10
+16.85%
|
-4.93
-113.86%
|
35.58
+1654.98%
|
-2.29
|
| Change In Payable |
|
-4.10
+16.85%
|
-4.93
-113.86%
|
35.58
+1654.98%
|
-2.29
|
| Change In Account Payable |
|
-6.21
-80.31%
|
-3.44
-110.84%
|
31.76
+1429.86%
|
-2.39
|
| Change In Other Working Capital |
|
0.71
-59.73%
|
1.76
+2276.54%
|
-0.08
-211.54%
|
-0.03
|
| Change In Other Current Assets |
|
—
|
—
|
3.74
+11787.50%
|
-0.03
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Investing Cash Flow |
|
-8.19
-151.98%
|
15.76
+294.71%
|
-8.10
+32.69%
|
-12.03
|
| Cash Flow From Continuing Investing Activities |
|
-8.19
-151.98%
|
15.76
+294.73%
|
-8.10
+32.69%
|
-12.03
|
| Net PPE Purchase And Sale |
|
-0.14
+77.81%
|
-0.64
-141.51%
|
-0.27
+7.99%
|
-0.29
|
| Purchase Of PPE |
|
-0.14
+77.81%
|
-0.64
-141.51%
|
-0.27
+7.99%
|
-0.29
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
-0.14
+77.92%
|
-0.64
-142.64%
|
-0.27
+17.96%
|
-0.32
|
| Net Investment Purchase And Sale |
|
—
|
—
|
-8.61
-1731.91%
|
-0.47
|
| Purchase Of Investment |
|
—
|
—
|
-9.35
-1889.57%
|
-0.47
|
| Sale Of Investment |
|
—
|
—
|
0.74
+239.91%
|
0.22
|
| Net Business Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-2.91
|
| Purchase Of Business |
|
—
|
0.00
|
0.00
+100.00%
|
-2.91
|
| Net Intangibles Purchase And Sale |
|
0.00
+100.00%
|
-0.00
|
0.00
+100.00%
|
-0.04
|
| Purchase Of Intangibles |
|
0.00
+100.00%
|
-0.00
|
0.00
+100.00%
|
-0.04
|
| Net Other Investing Changes |
|
-13.58
-265.08%
|
8.23
+180.42%
|
-10.23
-16.13%
|
-8.81
|
| Financing Cash Flow |
|
547.31
+1840.32%
|
28.21
-91.59%
|
335.29
+940.92%
|
32.21
|
| Cash Flow From Continuing Financing Activities |
|
547.31
+1840.32%
|
28.21
-91.59%
|
335.29
+940.88%
|
32.21
|
| Net Issuance Payments Of Debt |
|
-59.53
-258.81%
|
37.49
+145.99%
|
15.24
+256.93%
|
-9.71
|
| Issuance Of Debt |
|
0.00
-100.00%
|
47.94
-14.14%
|
55.84
|
0.00
|
| Repayment Of Debt |
|
-59.53
-469.26%
|
-10.46
+74.24%
|
-40.60
-318.10%
|
-9.71
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
47.94
-14.14%
|
55.84
|
0.00
|
| Long Term Debt Payments |
|
-59.53
-469.26%
|
-10.46
+74.24%
|
-40.60
-318.10%
|
-9.71
|
| Net Long Term Debt Issuance |
|
-59.53
-258.81%
|
37.49
+145.99%
|
15.24
+256.93%
|
-9.71
|
| Net Common Stock Issuance |
|
648.12
+149237.33%
|
0.43
-99.88%
|
353.39
+662.04%
|
46.37
|
| Cash Dividends Paid |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
5.82
|
0.00
|
0.00
-100.00%
|
0.00
|
| Net Other Financing Charges |
|
-40.61
-1913.58%
|
-2.02
+92.81%
|
-28.06
-6320.37%
|
-0.44
|
| Changes In Cash |
|
382.71
+447.60%
|
-110.10
-147.86%
|
230.06
+781.65%
|
-33.75
|
| Effect Of Exchange Rate Changes |
|
-10.25
-530.35%
|
2.38
+146.96%
|
-5.07
|
0.00
|
| Beginning Cash Position |
|
144.22
-42.76%
|
251.94
+834.85%
|
26.95
-55.60%
|
60.70
|
| End Cash Position |
|
516.68
+258.26%
|
144.22
-42.76%
|
251.94
+834.85%
|
26.95
|
| Free Cash Flow |
|
-161.27
-4.24%
|
-154.72
-58.85%
|
-97.39
-79.50%
|
-54.26
|
| Change In Income Tax Payable |
|
2.11
+241.90%
|
-1.49
-138.92%
|
3.82
+3721.00%
|
0.10
|
| Change In Tax Payable |
|
2.11
+241.90%
|
-1.49
-138.92%
|
3.82
+3721.00%
|
0.10
|
| Common Stock Issuance |
|
648.12
+149237.33%
|
0.43
-99.88%
|
353.39
+662.04%
|
46.37
|
| Interest Paid CFF |
|
-6.49
+15.67%
|
-7.70
-45.79%
|
-5.28
-31.48%
|
-4.01
|
| Interest Paid CFO |
|
—
|
—
|
—
|
—
|
| Interest Received CFI |
|
5.53
-32.38%
|
8.18
+240.75%
|
2.40
+12531.58%
|
0.02
|
| Interest Received CFO |
|
—
|
—
|
—
|
—
|
| Issuance Of Capital Stock |
|
648.12
+149237.33%
|
0.43
-99.88%
|
353.39
+662.04%
|
46.37
|
| Other Cash Adjustment Inside Changein Cash |
|
4.73
|
0.00
|
0.00
|
—
|
| Other Cash Adjustment Outside Changein Cash |
|
—
|
—
|
-0.00
+66.67%
|
-0.00
|
| Taxes Refund Paid |
|
—
|
—
|
—
|
—
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|